Form 4: Director Richard Barry Acquires 16,875 SRPT Shares

Sarepta Therapeutics Director Richard Barry was granted 16,875 restricted stock units as part of annual equity compensation.

Summary

• Director Richard Barry acquired 16,875 restricted stock units (RSUs) of Sarepta Therapeutics common stock on June 4, 2026.
• Each RSU represents a right to receive one share of common stock.
• The RSUs are scheduled to vest on the earlier of the one-year anniversary of the grant or the next annual meeting of stockholders.
• Following this transaction, the director's direct beneficial ownership increased to 2,983,542 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Director maintains a significant long-term equity stake in the company, signaling alignment with shareholder interests.
• The acquisition reflects standard equity-based compensation for board members.

Negatives

• None identified.

Risks

• Standard market risks associated with holding equity in a biotechnology company.

Future Outlook

The RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided the meeting is at least 50 weeks after the previous year's meeting.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the biotechnology sector to ensure board members remain incentivized to drive long-term corporate value.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard corporate governance practices for NASDAQ-listed biotechnology firms.
• The vesting schedule aligns with typical annual equity compensation cycles observed in the industry.

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation.
• Director: Increased equity exposure to company performance.

Next Steps

• Vesting of the 16,875 RSUs upon the earlier of the one-year anniversary or the next annual meeting.

Key Dates

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Trading, Director Compensation, Biotech